Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GameStop Corp. (GME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GameStop Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while GameStop Corp. trades at $21.65 (market cap $9.73B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.1× GameStop Corp.'s market cap, and GameStop Corp. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GME | |
|---|---|---|
Market Cap | $39.89B | $9.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $27.69 |
52-Week Low | $278.09 | $19.94 |
Enterprise Value | $38.15B | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GME trades at $21.68, down 1.23% today, with bearish technical signals from moving averages and a neutral RSI. Recent earnings beats in Q3 2025 through Q1 2026 show improving profitability, with net income margin at 20.45% for 2025. The company's strategic pivot includes pursuing an eBay acquisition and focusing on collectibles growth, supported by a strong balance sheet with $4.77B in cash and low debt-to-asset ratio of 0.28.
Outlook is mixed: strong fundamentals and strategic initiatives offer upside, but technical weakness and competitive risks in physical media decline pose challenges. Analyst consensus is cautious with only 16.67% buy ratings, reflecting skepticism over execution of ambitious plans like the eBay bid amid shifting industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
